The effect of Montelukast administration on rhabdomyolysis state

The effect of routine rhabdomyolysis treatment with and without concomitant administration of Montelukast on the stop progression and recovery time of rhabdomyolysis

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210720051946N2

Enrollment

Registered

2022-05-19

Start date

2022-05-22

Completion date

Unknown

Last updated

2022-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rhabdomyolysis. Rhabdomyolysis

Interventions

Intervention 1: Control group:Includes odd numbers in the numbered list of patients undergoing routine rhabdomyolysis (24-hour maintenance fluid therapy plus one liter of Normal saline per 1000 units

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients that admit with drug or substance toxicity and progress to rhabdomyolysis

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Cpk. Timepoint: Daily. Method of measurement: Labratory.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactPeyman Erfantalab Avini

Shahid Beheshti University of Medical Sciences

peyman1346erfan@sbmu.ac.ir+98 21 5102 5000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026